Conference Description:

Returning for the 5th year, the Macrophage-Directed Therapies Summit is your must-attend meeting to deep dive into biological cell plasticity and better understand how to reprogram and target macrophages within oncology, autoimmunity and inflammatory diseases.

Uniting experts across discovery, translation and clinical development, join this unique forum to benchmark relevant biomarkers for patient selection, scale-up engineered CAR-M, unlock optimal combinations and validate the next generation of therapies Gain competitor insights from those targeting CD47, SIRP?, VISTA, CD40, CD24 and more, to drive progression and safeguard established macrophage modulators.

Boasting clinical trial data, join industry leaders to gain translational lessons learned to assess the potential of macrophages as a monotherapy and through combination strategies, to guarantee clinical success of adoptive cell therapies, bispecifics and next-gen macrophage-directed therapies.



URL:
Tickets: https://go.evvnt.com/1868801-2?pid=154
Time: 8:30 AM - 5:00 PM

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4646.00,
Drug Developer Pricing - Conference Only: USD 2899.00,
Academic Pricing - Conference + Workshop Day: USD 3996.00,
Academic Pricing - Conference Only: USD 2499.00,
Vendor Pricing - Conference + Workshop Day: USD 5696.00,
Vendor Pricing - Conference Only: USD 3599.00

Speakers: Abe Maingi, Co-Founder and Vice President, Business Development, Inceptor Bio, Andrew Pincetic, Director, Immuno-Neurology, Alector, Daniela Schloesser, Senior Scientist, Boehringer Ingelheim, David Ralph, Senior Director, Drug Discovery, Navidea Biopharmaceuticals, David Rodgers, Senior Director, Macrophage Cell Therapy, Shoreline Biosciences, David Young, Chief Executive Officer, KisoJi Biotechnology Inc., Debashis Sahoo, Associate Professor, University of California School of Medicine, George Fromm, Chief Scientific Officer, Shattuck Labs, Jennifer Guerriero, Assistant Professor, Harvard Medical School, Judith Varner, Professor, Pathology, UC San Diego, Karim Christian El Kasmi, Senior Associate Director, Boehringer Ingelheim, Kipp Weiskopf, Valhalla Whitehead Fellow, Whitehead Institute, Michael Brehm, Associate Professor, Molecular Medicine, UMass Chan Medical School, Michael Klichinsky, Co-Founder and Chief Scientific Officer, Carisma Therapeutics, Michael McGrath, Professor Emeritus of Medicine, UCSF, Nathanael McCurley, Co-Founder and Vice President, Research and Development, SIRPant ImmunoTherapeutics, Roy Noy, Senior Staff Scientist, Regeneron Pharmaceuticals, Stephen Myatt, Chief Executive Officer, Macomics, Stuart Hughes, Chief Executive Officer, Pathios Therapeutics, Sumiti Jain Vice President, Research and Development, Inceptor Bio, Tatiana Novobrantseva, Chief Scientific Officer, Immunology, Moderna, Thierry Guillaudeux, Chief Scientific Officer, Kineta Inc., Thomas Marron, Director, Early Phase Trials Unit, Associate Professor of Medicine and Immunology, Icahn School of Medicine at Mount Sinai, Tomasz Rygiel, Co-founder and Chief Scientific Officer, Cellis, Zdravka Medarova, Chief Technology Officer, TransCode Therapeutics